Title (en)

Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy

Title (de)

Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung

Title (fr)

Composés azabicycliques, compositions pharmaceutiques les contenant et leur utilisation thérapeutique

Publication

EP 0499313 B1 19970611 (EN)

Application

EP 92200303 A 19920204

Priority

- GB 9102809 A 19910211
- GB 9107403 A 19910409
- GB 9113892 A 19910627
- GB 9114553 A 19910705

Abstract (en)

[origin: EP0499313A1] Compounds of formula (I), and salts and prodrugs thereof <CHEM> wherein Q is the residue of an optionally substituted azabicyclic ring system; X represents oxa or thia; Y represents H or hydroxy; R<1> and R<2> independently represent phenyl or thienyl, either of which groups may be optionally substituted by halo or trifluoromethyl; R<3>, R<4> and R<5> independently represent H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR<a>, SCH3, SOCH3, SO2CH3, -NR<a>R<b>, -NR<a>COR<b>, -NR<a>CO2R<b>, -CO2R<a> or -CONR<a>R<b>; and R<a> and R<b> independently represent H, C1-6 alkyl, phenyl or trifluoromethyl, are tachykinin antagonists. They and compositions thereof are therefore useful in therapy.

IPC 1-7

C07D 453/02; C07D 487/08; A61K 31/435; A61K 31/40; C07F 7/08

IPC 8 full level

A61K 31/40 (2006.01); **A61K 31/435** (2006.01); **A61P 1/00** (2006.01); **A61P 11/00** (2006.01); **A61P 25/04** (2006.01); **A61P 25/18** (2006.01); **A61P 25/20** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 37/06** (2006.01); **C07D 453/02** (2006.01); **C07D 487/08** (2006.01)

CPC (source: EP US)

A61P 1/00 (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/20** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **C07D 453/02** (2013.01 - EP US); **C07D 487/08** (2013.01 - EP US)

Cited by

GB2268931A; US5387595A; US6048859A; US5952330A; US6090819A; US5627211A; GB2269170A; US5561130A; AU675786B2; US5869499A; US5633281A; US5610165A; US5633266A; AU679207B2; US5922706A; US5872116A; US5719147A; US5830854A; US5637699A; US5344830A; EP0533280A1; US5360820A; US5538982A; US5798363A; US5691336A; US5939434A; US5780467A; US5512570A; US5716942A; US5624947A; EP0829480A3; US9156812B2; EP0722736A1; WO2006123182A2; WO9419323A1; WO9407843A1; WO9414767A1; US8420811B2; US8445494B2; WO9402461A1; WO9321181A1; WO9416697A1; WO2012087772A1; WO2012145471A1; US7687630B2; US7214692B2; US7342028B2; WO2010132487A1; WO2007093827A1; US7084152B2; US7309789B2; US7419985B2; WO2014120748A1; WO2012030685A2; EP3103791A1; WO2009002495A1; EP4079856A1; WO9502595A1; WO9413663A1; WO9415903A1; US7163949B1; EP0769300A2; WO2015034925A1; WO2008090117A1; WO2020033282A1; EP0774250A1; WO2012027236A1; WO2013165816A2; WO2014085216A1; EP3919620A1; WO2012036997A1; US8227486B2; US8236796B2; WO2013063214A1; WO2014052563A2; WO2019094311A1; US11096950B2; US7541357B2; US6638930B2; US6235735B1; EP0717998A1; WO2011046771A1; US9604960B2; WO2020033284A1; WO2010000073A1; US6709651B2; WO2012058210A1; EP3327125A1; EP3766975A1; US7612090B2; US6579885B2; US7265116B2; WO2010132442A1; WO2012018754A2; EP3330377A1; WO2007011820A2; EP0722722A1; WO2010114780A1; US7956050B2; EP2336120A1; WO2014100065A1; US8791101B2; EP2805945A1; US9403776B2

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IT LI LU NL PT SE

DOCDB simple family (publication)

EP 0499313 A1 19920819; **EP 0499313 B1 19970611**; AT E154354 T1 19970615; CA 2060949 A1 19920812; DE 69220258 D1 19970717; DE 69220258 T2 19971218; IE 920435 A1 19920812; JP 2500279 B2 19960529; JP H0578354 A 19930330; US 5242930 A 19930907

DOCDB simple family (application)

EP 92200303 A 19920204; AT 92200303 T 19920204; CA 2060949 A 19920210; DE 69220258 T 19920204; IE 920435 A 19920210; JP 2506892 A 19920212; US 83082292 A 19920204